3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
11
Carcinoma, Hepatocellular
9
Squamous Cell Carcinoma of Head and Neck
5
Small Cell Lung Carcinoma
5
Neoplasms
5
Lung Neoplasms
5
Colorectal Neoplasms
4
Sarcoma, Alveolar Soft Part
3
Carcinoma, Renal Cell
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Solid Tumors
2
Sarcoma
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Liver Neoplasms
2
Extensive Stage Lung Small Cell Carcinoma
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Unresectable Hepatocellular Carcinoma
1
Stomach Neoplasms
1
Small Cell Lung Cancer Extensive Stage
1
Rhabdoid Tumor
1
Papillary renal cell carcinoma, sporadic
1
PIK3CA-Mutated Cancers
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Interventions
tremelimumab
1
durvalumab
1
atezolizumab
1
Bumetanide
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unresectable Hepatocellular Carcinoma
×
atezolizumab
×
30 days
×
Clear all
NCT06117891
2026-05-12
REFINE-IO
Bayer
Active not recruiting
300 enrolled